Powder: -20°C for 3 years | In solvent: -80°C for 1 year
IC261 (SU-5607) 是一种选择性的,ATP 竞争性的CK1抑制剂,可触发有丝分裂检查点控制。对Ckiδ、Ckiε、 Ckiα1 和Cdk5的IC50值分别为 1 μM、1 μM 、16 μM 和4.5mM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 245 | 现货 | ||
5 mg | ¥ 613 | 现货 | ||
10 mg | ¥ 933 | 现货 | ||
25 mg | ¥ 1,990 | 现货 | ||
50 mg | ¥ 3,180 | 现货 | ||
100 mg | ¥ 4,590 | 现货 | ||
500 mg | ¥ 9,550 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 667 | 现货 |
产品描述 | IC261 (SU-5607) is a novel inhibitor of CK1, triggers the mitotic checkpoint control. The IC50 of IC261 for CK1 was 16 μM and for Cdk5 is 4.5 mM. |
靶点活性 | CK1:16 μM, CDK5:4.5 mM. |
体外活性 | IC261 leads to a p53-dependent arrest of the cells with a DNA content of 4 N. It can produce effects on cell cycle progression that are indistinguishable from an established spindle poison and are dependent on the p53 status of the cells[1]. |
体内活性 | Intrathecal injection of a CK1 inhibitor IC261 attenuates neuropathic pain behaviors. CK1 inhibitors are found to be effective in reducing spinal excitatory response elicited by the presynaptic electrical stimulation only in neuropathic mice[2]. Targeting CK1 isoforms by IC261 influences both pancreatic tumour cell growth and apoptosis sensitivity in vitro and the growth of induced tumours in vivo[3]. |
细胞实验 | Cultures of MEFs of di?erent genotypes (p53+/+, p53+/7, p537/7) are treated with the inhibitor IC261 in the low micromolar range (1 μM). After 12, 24, 48 hours exposure, the effects of IC261 on cell cycle distribution are measured by flow cytometry.(Only for Reference) |
别名 | SU-5607 |
分子量 | 311.33 |
分子式 | C18H17NO4 |
CAS No. | 186611-52-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 58 mg/mL (186.3 mM)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 3.212 mL | 16.0601 mL | 32.1203 mL | 80.3006 mL |
5 mM | 0.6424 mL | 3.212 mL | 6.4241 mL | 16.0601 mL | |
10 mM | 0.3212 mL | 1.606 mL | 3.212 mL | 8.0301 mL | |
20 mM | 0.1606 mL | 0.803 mL | 1.606 mL | 4.015 mL | |
50 mM | 0.0642 mL | 0.3212 mL | 0.6424 mL | 1.606 mL | |
100 mM | 0.0321 mL | 0.1606 mL | 0.3212 mL | 0.803 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
IC261 186611-52-9 Apoptosis Cell Cycle/Checkpoint Metabolism Stem Cells Casein Kinase CDK Inhibitor inhibit IC-261 SU 5607 SU5607 IC 261 SU-5607 inhibitor